|
FY2026
12 months to Jun 30, 2026
|
FY2025
12 months to Jun 30, 2025
|
FY2024
12 months to Jun 30, 2024
|
FY2023
12 months to Jun 30, 2023
|
FY2022
12 months to Jun 30, 2022
|
|
|---|---|---|---|---|---|
| Revenue | |||||
| License revenue | |||||
| Other income | |||||
| Research material sales | |||||
| Grant income | |||||
| Net gain on foreign exchange | |||||
| Fair value gain on financial assets | |||||
| Net gain on fair value movement of warrants | |||||
| Interest income | |||||
| Miscellaneous | |||||
| Total revenue and other income | |||||
| Expenses | |||||
| Research & development and intellectual property expenses | |||||
| Corporate administrative expenses | |||||
| Net loss on foreign exchange | |||||
| Finance costs | |||||
| Net Changes in fair value of convertible note liability | |||||
| Net change in fair value of derivative financial instrument | |||||
| Loss before income tax expense | |||||
| Income tax expense | |||||
| Loss after income tax expense for the year | |||||
| Other Comprehensive Income/(Loss) | |||||
| Exchange differences on the translation of foreign operations | |||||
| Other comprehensive income/(loss) for the year, net of tax | |||||
| Total comprehensive loss for the year | |||||
| Loss for the year is attributable to: | |||||
| Owners of Immutep Limited | |||||
| Total comprehensive loss for the year is attributable to: | |||||
| Owners of Immutep Limited | |||||
| Basic loss per share | |||||
| Diluted loss per share | |||||
Loading...